Source link : https://www.newshealth.biz/health-news/novel-agent-curbs-alzheimers-related-agitation/
Treatment with AXS-05, a combination of dextromethorphan and bupropion, demonstrated rapid, sustained, and clinically meaningful improvement in agitation related to Alzheimer’s disease (AD) and was generally well tolerated in the phase 3 ACCORD trial. More than half of participants in the open-label extension period of the randomized clinical trial responded to the medication, which was […]
Author : News Health
Publish date : 2024-04-23 18:42:13
Copyright for syndicated content belongs to the linked Source.